Trial Profile
Cytoreductive treatment of dabrafenib combined with trametinib to allow complete surgical resection in patients with BRAF mutated, prior unresectable stage III or IV melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms REDUCTOR
- 24 Oct 2023 Results assessing update of long-term relapse-free survival (RFS), progression-free survival (PFS) and overall survival (OS), presented at the 48th European Society for Medical Oncology Congress.
- 01 Aug 2021 Primary endpoint (Complete resection rate) has been met as per results published in the Annals of Surgery
- 01 Aug 2021 Results published in the Annals of Surgery